SynthesisBMJ (Clinical research ed.)2017
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Synthesis in BMJ (Clinical research ed.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.British journal of clinical pharmacology · 2018Pooled it
- Navigating the Prescription Drug Information System.Clinical pharmacology and therapeutics · 2026Review
- Model-Informed Drug Development (MIDD) for Analgesics: Review of Applications, Regulatory Integration, and Emerging Directions.Journal of pain research · 2026Review
- Current landscape of US Food and Drug Administration use of expedited regulatory approvals for colorectal cancer care.Journal of managed care & specialty pharmacy · 2025Article
- Putting the substance in substantial evidence: an evidence-based approach to flexible drug regulation.Frontiers in medicine · 2025Article
- Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification.PharmacoEconomics · 2025Article
- Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review.PharmacoEconomics - open · 2024Article
- Analysis of post-marketing requirements for oncology drug conditional approvals in the United States and China.Heliyon · 2024Article
- Towards a coordinated approach for managing accelerated patient access to potentially beneficial medicines: reporting the perspectives of a multi-stakeholder, international workshop.Health affairs scholar · 2024Article
- The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.Drug safety · 2024Article
- Article
- Observational
- Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.JAMA health forum · 2022Article
- Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.JAMA health forum · 2022Article
- The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada.Healthcare policy = Politiques de sante · 2022Article
- An urgent call to raise the bar in oncology.British journal of cancer · 2021Review
- US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.Clinical trials (London, England) · 2021Article
- Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies.Medical decision making : an international journal of the Society for Medical Decision Making · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.